biostudies-literatureUnknown2022Wang Y<h4>Introduction</h4>There has been controversy about renin-angiotensin system (RAS) inhibition in IgAN patients with advanced (stage 4) chronic kidney disease (CKD). Therefore, we investigated the effect of RAS blockade in these patients.<h4>Methods</h4>Renal specimens of 50 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2020, were stained using immunohistochemistry to detect the expression of RAS receptors (AT1R, AT2R, MasR, and MrgD). The primary endpoint was a composite of end-stage renal disease (ESRD) and death. Main baseline information and the administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) were collected.<h4>Results</h4>During a median follow-up time of 25.5 months, 21 (42.0%) patients reached Journal of the renin-angiotensin-aldosterone system : JRAAS9162427https://www.ebi.ac.uk/biostudies/studies/S-EPMC9822756biostudies-literatureIgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m² May Still Benefit from RAS Inhibition.PMC9822756Zhuo LLi WJiang SWang YZou GfalseIgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m² May Still Benefit from RAS Inhibition.<h4>Introduction</h4>There has been controversy about renin-angiotensin system (RAS) inhibition in IgAN patients with advanced (stage 4) chronic kidney disease (CKD). Therefore, we investigated the effect of RAS blockade in these patients.<h4>Methods</h4>Renal specimens of 50 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2020, were stained using immunohistochemistry to detect the expression of RAS receptors (AT1R, AT2R, MasR, and MrgD). The primary endpoint was a composite of end-stage renal disease (ESRD) and death. Main baseline information and the administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) were collected.<h4>Results</h4>During a median follow-up time of 25.5 months, 21 (42.0%) patients reached 2022-01-01T00:00:00Z20222025-04-04T11:10:50.969Z2025-04-04T11:10:50.969ZS-EPMC98227563666042010.1155/2022/9162427